Sandoz Requests Calif. Court Make Final Ruling in Amgen SCOTUS Case

Generic Line
A A
Following the U.S. Supreme Court’s defining decision on the biosimilar “patent dance” and approval process, Sandoz has requested that an unresolved part of its case against Amgen return to a California federal district court.

To View This Article:

Login

Subscribe To Generic Line